Chinese Medicine - Modern Practice (252 pages)

66 I? Liu et al.
structure recovered likely), I, 111, IV type collagen expression decrease or
disappear in most patients. All these suggest that this recipe is effective
in treating chronic hepatitis B, especially in inhibiting liver fibrosis (Liu
et al., 1998c) (Fig. 6.3).
Furthermore, multi-center, randomised, double blinded and paralleled
controlled trials were conducted on 21 6 patients with liver fibrosis in
chronic hepatitis B (110 cases in trial group, 106 in control group, of
which 99 cases in trial and 96 in the control group received histological
diagnosis) in five centres receiving 24-week clinical treatment.
Results from 93 patients with liver fibrosis in chronic hepatitis B
under liver biopsy examination before and after treatment reveal that
liver fibrosis degree in FZHY decreases significantly with the mean value
of liver fibrosis staging (S) in FZHY (50 cases) being 2.33 before treatment
and 1.80 after FZHY treatment, while there is no improvement in the
control group with the mean value of liver fibrosis staging (S) control
group (43 cases) being 2.11 before treatment and 2.14 after treatment.
Liver biopsy revealed that reversion rate (judged by liver fibrosis staging)
is 52% in FZHY group and 23.3% in the control group, showing significant
difference between the two groups. Histological examination showed that
FZHY has obvious effect against liver fibrosis and is superior to that of
Heluo Shugan capsule. Furthermore, liver histological examination also
suggested that FZHY helps improve liver tissue inflammatory activity
and is superior to that of the control group in that it can decrease not only
mean value of inflammatory activity, but also inflammation score. These
demonstrate that FZHY is able to alleviate inflammatory cell infiltration
and or hepatic cell necrosis.
Parameters for liver fibrosis (HA, LM, P-111-P, IV-C) reveal that
there is no significant difference in serum content of HA, LM, P-111-P,
IV-C between the two groups before treatment. Each parameter in the
FZHY group at 12- and 24-week treatments decrease significantly
compared to that of pre-treatment, the differentials between 12- and 24-
week treatment, and pre-treatment in all parameters (except LM at
24-week treatment) are significantly greater than that of the control group.
The effectual is defined as two of four parameters of serum IV-C, HA,
LN and P-111-P after treatment lowers equal to or more than 30% of
baseline value compared to that of before treatment. According to this